NATERA INC (Common Stock) – ticker 45E

Company Overview

Business Model: Natera, Inc. is a diagnostics company leveraging proprietary cell-free DNA (cfDNA) technology, combining novel molecular assays with statistical algorithms, to identify genetic variations with high accuracy and coverage. The company aims to integrate personalized genetic testing and diagnostics into standard care across oncology, women’s health, and organ health to inform earlier and more targeted interventions. Natera, Inc. generates revenue primarily through the sale of its tests, with a significant portion derived from its Panorama, Horizon, and Signatera tests. The company also offers a cloud-based distribution model, Constellation, which licenses its bioinformatics algorithms to other laboratories.

Market Position: Natera, Inc. operates in highly innovative and rapidly changing molecular diagnostic testing markets. In women's health, its Panorama non-invasive prenatal test (NIPT) is a market leader by volume in the United States. The company emphasizes its core technology, which measures thousands of single nucleotide polymorphisms (SNPs) simultaneously, enabling high sensitivity and specificity in detecting genetic variations from tiny amounts of DNA. Natera, Inc. differentiates itself through extensive peer-reviewed clinical evidence (over 350 publications as of December 31, 2025) and a strong intellectual property portfolio (over 650 issued or pending patents). Key competitive factors include test performance, comprehensiveness, value, reimbursement coverage, sales effectiveness, distribution breadth, and reputation.

Recent Strategic Developments:

• Acquisition of Foresight Diagnostics, Inc.: In December 2025, Natera, Inc. acquired Foresight Diagnostics, Inc., a cancer diagnostics company specializing in circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) tests using patented PhasED-Seq™ technology. This acquisition expands Natera, Inc.'s intellectual property portfolio for tumor-informed and personalized MRD products, including phased variants, and extends its focus to include lymphoma. The total purchase consideration was $424.5 million, including common stock and contingent consideration.
• Product Launches:
  • Latitude: A blood-based MRD test for colorectal cancer that does not require a tumor tissue sample, launched recently.
  • Fetal RhD NIPT: Launched in 2024, this test assesses fetal rhesus factor (RhD) status with greater than 99% sensitivity and specificity.
  • Fetal Focus: A single-gene NIPT screening for 21 single-gene inherited conditions, designed to address unmet needs when partner testing is unavailable or incomplete.
• Clinical Evidence Generation: Continued investment in generating scientific and clinical evidence, including the SMART study for Panorama and ongoing studies for Signatera across multiple cancer types.
• International Expansion: Products are offered in over 80 countries, primarily through laboratory and distribution partners. Natera, Inc. has received CE Marks for its Constellation software and key reagents, and for the Panorama test as a whole, enabling its offering as an in vitro diagnostic (IVD) in the European Union.

Geographic Footprint: Natera, Inc. is headquartered in Austin, Texas, with laboratory facilities in Austin, Texas, San Carlos, California, and Boulder, Colorado. The company's operations are primarily conducted in the United States, which accounted for 98% of total revenues in 2025. International revenues were $41.8 million in 2025, representing 2% of total revenues, with products offered in over 80 countries through partners.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 64.7%
• Operating Margin: -13.4%
• Net Margin: -9.0%

Investment in Growth:

• R&D Expenditure: $624.1 million (27.1% of revenue)
• Capital Expenditures: $106.2 million
• Strategic Investments: The acquisition of Foresight Diagnostics, Inc. for a total purchase consideration of $424.5 million in December 2025, primarily to expand the intellectual property portfolio for tumor-informed and personalized MRD products and build on clinical research in B-cell lymphomas.

Business Segment Analysis

Natera, Inc. operates as a single reporting segment focused on the development and commercialization of molecular testing services across oncology, women’s health, and organ health. The company's Chief Executive Officer, as the Chief Operating Decision Maker (CODM), evaluates overall financial performance and makes key operating decisions based on consolidated financial statements.

Oncology

Financial Performance:

• Total oncology units processed: Approximately 800,800 in 2025 (+51.6% YoY from 528,200 in 2024).
• Key Growth Drivers: Continued commercial growth of Signatera, expansion into new cancer types (e.g., lymphoma via Foresight Diagnostics, Inc. acquisition), and development of early cancer detection tests.

Product Portfolio:

• Signatera: Personalized ctDNA blood test for molecular residual disease (MRD) assessment, early recurrence monitoring, and treatment response evaluation in cancer patients. It is custom-designed for each patient's tumor-specific clonal mutations.
• Latitude: Blood-based MRD test for colorectal cancer that does not require a tumor tissue sample.
• Altera: Tissue-based comprehensive genomic profiling test for therapy selection.
• Empower: Hereditary cancer screening test, also offered through the women's health channel.
• New Product Launches/Updates: Acquisition of Foresight Diagnostics, Inc. expanded focus to include lymphoma and leverages patented PhasED-Seq™ technology for ctDNA-based MRD tests.

Market Dynamics:

• Competitive Positioning: Signatera's tumor-informed approach is believed to be optimal for MRD detection, even at very low variant allele frequencies.
• Total Addressable Market (U.S.): Estimated at approximately $21 billion for recurrence monitoring for solid tumor cancers (including immunotherapy treatment response monitoring) and approximately $3 billion for blood cancers. Therapy selection represents an approximate $7.0 billion market opportunity.
• Reimbursement: Signatera is covered by Medicare for certain colorectal, muscle invasive bladder, advanced breast, and advanced ovarian cancers, non-small cell lung cancer surveillance, and immunotherapy response monitoring for all solid tumor types. It has Advanced Diagnostic Laboratory Test (ADLT) status and Breakthrough Device Designations from the FDA.

Women’s Health

Financial Performance:

• Key Growth Drivers: Continued commercial growth of Panorama and Horizon, increasing adoption of NIPT for average-risk pregnancies, and new product launches like Fetal RhD NIPT and Fetal Focus.
• Reimbursement: NIPT has positive coverage determinations for high-risk pregnancies from most commercial health insurers. Reimbursement for average-risk pregnancies has improved, with most commercial health insurers and an increasing number of state Medicaid programs providing positive coverage. However, reimbursement rates for microdeletions testing under the specific CPT code remain low.

Product Portfolio:

• Panorama: Non-invasive prenatal test (NIPT) for fetal chromosomal abnormalities (e.g., Down syndrome, Edwards syndrome, Patau syndrome, Turner syndrome, triploidy) and five common microdeletions. It can also identify fetal sex and zygosity in twin pregnancies.
• Horizon: Carrier screening test for up to 835 inherited conditions, offered across various screening panels.
• Fetal RhD NIPT: Assesses fetal rhesus factor (RhD) status.
• Fetal Focus: Single-gene NIPT screening for 21 single-gene inherited conditions.
• Vistara: Single-gene NIPT screening for 25 single-gene conditions affecting quality of life, often associated with cognitive disabilities.
• Anora: Products of conception (POC) test to analyze miscarriage tissue for underlying chromosomal reasons.
• Empower: Hereditary cancer screening test, also offered through the oncology channel.

Market Dynamics:

• Competitive Positioning: Panorama is positioned as the most accurate NIPT commercially available in the United States, based on published data. The SMART study demonstrated high sensitivity and specificity for T21 and 22q11.2 deletion syndrome.
• Key Customer Types: OB/GYNs, Maternal Fetal Medicine (MFM) specialists, and IVF centers.
• Market Trends: Evolution from ethnicity-specific to pan-ethnic and expanded carrier screening. Increasing recognition of NIPT for average-risk pregnancies.
• Total Addressable Market (U.S.): Estimated at approximately 1.0 million high-risk and 4.36 million average-risk pregnancies annually.

Organ Health

Financial Performance:

• Key Growth Drivers: Increasing adoption of Prospera for transplant rejection assessment and Renasight for chronic kidney disease.

Product Portfolio:

• Prospera: Test to assess active rejection in solid organ transplant patients by measuring donor-derived cell-free DNA (dd-cfDNA). Available for kidney, heart, and lung transplants.
• Renasight: Kidney gene panel test for 397 genes associated with chronic kidney disease (CKD) or increased hereditary risk.

Market Dynamics:

• Competitive Positioning: Prospera offers a non-invasive alternative to biopsies and has demonstrated strong performance in detecting rejection earlier than traditional methods.
• Total Addressable Market (U.S.): Estimated at over $3.8 billion for kidney, heart, and lung transplant rejection tests.
• Reimbursement: Prospera Kidney is covered by Medicare for all kidney transplant recipients. Prospera Heart is covered by Medicare for heart transplant patients. Prospera Lung is covered by Medicare for lung transplant patients in the surveillance setting.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed in the filing.
• Dividend Payments: Natera, Inc. has never declared or paid any cash dividends on its capital stock and does not anticipate doing so in the foreseeable future.
• Future Capital Return Commitments: Not disclosed.

Balance Sheet Position (as of December 31, 2025):

• Cash and Equivalents: $1,076.1 million
• Total Debt: $80.3 million (outstanding balance on Credit Line, including accrued interest)
• Net Cash Position: $995.8 million
• Credit Rating: Not disclosed.
• Debt Maturity Profile: The Credit Line with UBS is a revolving line of credit with an outstanding balance of $80.3 million as of December 31, 2025. UBS has the right to demand full or partial payment and terminate the credit line at any time. The interest rate is variable, set at the 30-day Secured Overnight Financing Rate (SOFR) average plus 0.5% as of October 2023.

Cash Flow Generation (Year Ended December 31, 2025):

• Operating Cash Flow: $215.3 million
• Free Cash Flow: Not explicitly stated, but operating cash flow is positive.
• Cash Conversion Metrics: Not explicitly detailed, but the company notes that approximately 90% of cash collections attributable to product revenue occur within 9 months, with the remaining generally taking an additional 6 months.

Operational Excellence

Production & Service Model: Natera, Inc. operates CLIA-certified laboratories in Austin, Texas, San Carlos, California, and Boulder, Colorado, where it performs commercial testing. The company's core technology combines proprietary molecular biology techniques (massively multiplexed polymerase chain reaction, or mmPCR) with computationally intensive algorithms to measure genomic variations. This approach allows for high signal-to-noise ratio in detecting DNA fragments at low frequencies. The Constellation platform enables a cloud-based distribution model, allowing international laboratories to run molecular workflows locally and access Natera, Inc.'s bioinformatics algorithms in the cloud.

Supply Chain Architecture: Key Suppliers & Partners:

• Sequencing Platform & Reagents: Illumina is the sole supplier of sequencers and related reagents for Panorama, Horizon, Signatera, and Prospera, along with certain hardware and software, under a supply agreement expiring in August 2033. Natera, Inc.'s molecular diagnostics tests are currently only validated to perform on Illumina's sequencing platform.
• Blood Collection Tubes: Streck is the sole supplier of blood collection tubes for Panorama and other cell-free DNA tests, with an exclusive supply arrangement for Panorama.
• Cloud Platform Service Provider: DNAnexus, Inc. hosts the majority of Natera, Inc.'s bioinformatics algorithms on third-party data center hosting facilities operated by Amazon Web Services (AWS). Natera, Inc. also hosts algorithms directly on AWS HealthOmics.
• Third-Party Laboratories: Natera, Inc. relies on third-party laboratories to perform portions of its service offerings.

Facility Network:

• Manufacturing: Not explicitly detailed as manufacturing, but laboratory facilities in Austin, Texas, San Carlos, California, and Boulder, Colorado are key for test processing.
• Research & Development: R&D activities are conducted at the laboratory facilities, including the Boulder, Colorado facility which performs clinical trials testing.
• Distribution: The company utilizes commercial courier delivery services to transport samples to its facilities.

Operational Metrics:

• Tests Processed: Approximately 3.5 million in 2025, compared to 3.1 million in 2024 and 2.5 million in 2023.
• Test Accessioned: Approximately 3,468,700 in 2025, compared to 3,001,900 in 2024 and 2,426,500 in 2023.
• Turnaround Times: The value of tests depends on timely delivery of results.
• Quality Indicators: The company emphasizes high accuracy and reproducibility, with continuous evaluation and refinement of testing processes.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Natera, Inc. employs a direct sales force and medical affairs professionals aligned by specialty (oncology, women's health, organ health) to engage healthcare providers in the United States.
• Channel Partners: A global network of over 100 laboratory and distribution partners, including large international laboratories, addresses local regulatory, reimbursement, and commercial requirements in over 80 countries.
• Digital Platforms: Marketing to healthcare providers through professional channels, including advertisements in peer-reviewed journals, educational webinars, medical conferences, and targeted digital outreach. NateraCore platform supports patient and provider experience with educational resources, insurance information, test ordering, and results reporting.

Customer Portfolio: Enterprise Customers:

• Tier 1 Clients: Collaborations with pharmaceutical companies and other partners on research, clinical development, and commercialization initiatives. Examples include an agreement with BGI Genomics Co., Ltd. to commercialize its MRD test in China and strategic collaboration agreements with Foundation Medicine, Inc.
• Customer Concentration: No single customer exceeded 10% of total revenues for the years ended December 31, 2025, 2024, and 2023. Medicare accounted for approximately 13.6% of total revenue in 2025.

Geographic Revenue Distribution (Year ended December 31, 2025):

• United States: 98.2% of total revenue ($2,264.3 million)
• Americas, excluding U.S.: 0.4% of total revenue ($9.4 million)
• Europe, Middle East, India, Africa: 1.1% of total revenue ($24.5 million)
• Asia Pacific and Other: 0.3% of total revenue ($8.0 million)

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The molecular testing field is characterized by rapid technological changes, frequent new product introductions, reimbursement challenges, emerging competition, intellectual property disputes, price competition, aggressive marketing, evolving industry standards, and changing customer preferences. Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Women's Health (NIPT & Carrier Screening): BGI, BillionToOne Inc., Fulgent Genetics, Illumina (through its subsidiary Verinata), Laboratory Corporation of America Holdings (Labcorp), Myriad Genetics, Inc., Quest Diagnostics Incorporated (Quest), and Revvity Inc.
• Oncology: BillionToOne Inc., Caris Life Sciences, Inc., Exact Sciences Corp., Guardant Health, Inc., Personalis, Inc., Quest, and Tempus Labs, Inc.
• Organ Health: CareDx, Inc.

Emerging Competitive Threats: New testing methods such as whole genome sequencing or single cell analysis for NIPTs, or tracking more tumor-specific variants and/or other biomarkers in addition to ctDNA for MRD testing. New entrants and disruptive technologies are expected.

Competitive Response Strategy: Natera, Inc. believes it compares favorably due to its core technology, continuous investment in scientific and clinical evidence, strong commercial teams, and enhanced user experience. The company is actively involved in intellectual property litigation to protect its technologies.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Demand Volatility: Market demand for tests is evolving, and physician recommendations and test orders are not guaranteed. Slowing growth in test volumes could negatively impact revenue.
• Technology Disruption: New testing methods (e.g., whole genome sequencing, single cell analysis) or advancements by competitors could render existing products uneconomical or inferior.
• Customer Concentration: While no single customer exceeds 10% of total revenue, Medicare represents a significant portion (13.6% in 2025), making the company sensitive to changes in Medicare policies.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Supplier Dependency: Reliance on a limited number of sole suppliers (e.g., Illumina for sequencers/reagents, Streck for blood collection tubes) creates risk. Disruptions, quality issues, or inability to find replacements could interrupt supply, increase costs, or delay test performance.
• Geographic Concentration: Laboratory facilities are in specific locations (Austin, San Carlos, Boulder), making them vulnerable to natural disasters or other localized disruptions.
• Capacity Constraints: Rapid growth in test volumes requires continuous scaling of testing capacity, headcount, equipment, and infrastructure. Failure to scale effectively could lead to higher costs or inability to meet demand.
• Third-Party Laboratory Reliance: Dependence on third-party laboratories for portions of service offerings introduces risks related to quality control, timeliness, and compliance with legal/regulatory requirements.
• Cybersecurity Threats: High dependence on information technology networks and systems for sensitive data (patient health information, intellectual property). Breaches or disruptions could lead to legal claims, penalties, operational disruptions, and reputational harm.
• AI/ML Risks: Integration of AI/ML technologies introduces risks of inaccurate outputs, information security vulnerabilities, and increased data privacy/intellectual property risks.

Financial & Regulatory Risks

Market & Financial Risks:

• Reimbursement Uncertainty: Inability to expand, maintain, or obtain third-party payer coverage and adequate reimbursement for tests (especially microdeletions) could adversely affect revenues. Recoupment requests from payers for alleged overpayments are a recurring risk.
• Indebtedness: The Credit Line with UBS is secured by collateral and can be demanded for payment or terminated at any time, potentially decreasing business flexibility.
• Net Losses: Natera, Inc. has incurred net losses since inception and anticipates continued losses, requiring additional capital raises which could dilute stockholders.
• Litigation: Involvement in legal proceedings (intellectual property, false advertising, billing, class action lawsuits) is costly, time-consuming, and could result in substantial damages, adverse judgments, or injunctions.

Regulatory & Compliance Risks:

• FDA Regulation of LDTs: Historically, the FDA exercised enforcement discretion over laboratory-developed tests (LDTs). While a recent FDA rule to regulate LDTs was vacated by a federal court, future regulatory changes or legislation (e.g., VALID Act) could subject Natera, Inc.'s LDTs to premarket authorization, incurring substantial costs and delays.
• Laboratory Licensing: Failure to comply with federal (CLIA) and state (California, New York) laboratory licensing requirements could lead to suspension or revocation of licenses, civil penalties, and inability to perform tests.
• Healthcare Fraud & Abuse Laws: Subject to federal and state anti-kickback, false claims, and self-referral laws (e.g., Anti-Kickback Statute, False Claims Act, Stark Law, EKRA). Violations could result in civil/criminal penalties, fines, and exclusion from federal healthcare programs.
• Privacy Laws: Compliance with HIPAA, GDPR, CCPA, and other evolving state and international privacy laws is complex. Non-compliance or data breaches could lead to fines, penalties, litigation, and reputational damage.
• RUO Products: Use of "research use only" (RUO) labeled reagents and equipment for clinical diagnostic use carries risk of FDA enforcement action against suppliers or Natera, Inc.

Geopolitical & External Risks

Geopolitical Exposure:

• International Operations: Expansion into foreign markets exposes Natera, Inc. to varied and complex foreign laws, economic and trade sanctions, and political/economic instability.
• Trade Relations: Restrictions on import/export of materials or data could limit international offerings.
• Macroeconomic Pressures: Inflation, rising interest rates, and supply chain issues could increase operating costs, negatively affect demand, and impact access to capital.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas: Natera, Inc. focuses on cell-free DNA (cfDNA) technology, combining novel molecular assays (massively multiplexed polymerase chain reaction, or mmPCR) with statistical algorithms. This technology reliably measures many informative regions across the genome from small samples to identify genetic variations. Innovation Pipeline:

• Oncology: Developing and clinically validating an early cancer detection test, initially focused on colorectal cancer. Continued generation of clinical evidence for Signatera across multiple cancer types.
• Women's Health: Recent technological advances validated in the SMART study for Panorama, leveraging artificial intelligence for highly accurate results.
• Organ Health: Generating data in multiple clinical studies to demonstrate clinical utility and benefits of the Prospera test.

Intellectual Property Portfolio:

• Patent Strategy: Natera, Inc. held over 650 issued or pending U.S. and foreign patents as of December 31, 2025, related to molecular diagnostics, biochemical, and analytical techniques for genetic information analysis. The company intends to seek patent protection for new technologies and products.
• IP Litigation: Natera, Inc. is actively involved in patent infringement lawsuits and other intellectual property disputes against various competitors, both as plaintiff and defendant.

Technology Partnerships:

• Strategic Alliances: Collaborates with pharmaceutical companies and other partners on research, clinical development, and commercialization initiatives. Examples include an agreement with BGI Genomics Co., Ltd. to commercialize its MRD test in China.
• Research Collaborations: Engages with leading universities, cancer centers, NIH’s National Cancer Institute (NCI), and non-profit cancer research groups.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The company's success depends significantly on its senior management team, including its founder and Executive Chairman, Matthew Rabinowitz, and Chief Executive Officer, Steve Chapman. The loss of key personnel could adversely affect the business.

Board Composition: The audit committee is responsible for oversight of information security, including cybersecurity risks, and includes two directors with expertise or certifications in cybersecurity.

Human Capital Strategy

Workforce Composition (as of December 31, 2025):

• Total Employees: 6,140 (6,135 full-time)
• Geographic Distribution: Not explicitly detailed, but global workforce.
• Skill Mix: Competition for highly qualified personnel is intense, especially for sales, scientific, medical, laboratory, research and development, and other technical personnel.
• Diversity: In 2025, women comprised approximately 64.2% of the global workforce, 65.7% of global new hires, and 63.8% of internal promotions. Minorities comprised approximately 39% of the U.S. workforce.

Talent Management: Acquisition & Retention:

• Hiring Strategy: Focused on attracting and retaining a diverse workforce.
• Retention Metrics: Employee engagement survey in 2024 showed an 84% engagement score, 91% of employees proud to work at Natera, Inc., and 80% would recommend Natera, Inc. as a great place to work.
• Employee Value Proposition: Compensation and benefits programs (base pay, annual bonuses, stock-based compensation, 401(k) with matching, healthcare, paid time off, parental leave, EAPs). Annual pay equity assessments.

Diversity & Development:

• Development Programs: Employee evaluation process supports development and identifies high performers. Initiatives are underway to further develop leaders and managers.
• Culture & Engagement: Growing number of employee resource groups (ERGs) to foster connection, support, and an inclusive culture.

Environmental & Social Impact

Environmental Commitments: Climate Strategy:

• Emissions Targets: Natera, Inc. established near-term science-based greenhouse gas emissions reduction targets validated by the Science Based Targets Initiative (SBTi) in 2025.
• Renewable Energy: Reviewing investment opportunities in renewable energy.
• Other Initiatives: Reducing energy and water consumption, greenhouse gas emissions, and waste production. Supply Chain Sustainability:
• Supplier Engagement: Not explicitly detailed beyond general environmental sustainability program.
• Responsible Sourcing: Not explicitly detailed beyond general environmental sustainability program.

Social Impact Initiatives:

• Community Investment: Not explicitly detailed.
• Product Impact: Natera, Inc.'s mission is to change disease management worldwide, aiming to protect health and inform earlier and more targeted interventions.
• Animal Testing: The company does not conduct animal testing.

Business Cyclicality & Seasonality

Demand Patterns:

• Seasonal Trends: Not explicitly detailed in the filing.
• Economic Sensitivity: Macroeconomic pressures (e.g., inflation, rising interest rates) may negatively affect demand for product offerings.
• Industry Cycles: Not explicitly detailed in the filing.

Planning & Forecasting: Not explicitly detailed in the filing beyond general business plan.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• CLIA & State Licensing: Natera, Inc.'s laboratories are CLIA-certified and CAP-accredited. They also hold state licenses in California and New York, and comply with their more stringent requirements.
• FDA Regulation of LDTs: Historically, the FDA exercised enforcement discretion over LDTs. While a May 2024 final rule to regulate LDTs was vacated by a federal court in May 2025, and subsequently rescinded by the FDA in September 2025, the regulatory landscape remains uncertain. Future legislation (e.g., VALID Act) or alternative FDA approaches could subject Natera, Inc.'s LDTs to premarket authorization.
• International Compliance: Tests and components are subject to regulatory approval in foreign countries. Natera, Inc. has CE Marks for Constellation software, key reagents, and the Panorama test for use as an IVD in the European Union. Trade & Export Controls:
• Export Restrictions: Subject to U.S. economic and trade sanctions, which restrict business in certain designated countries.
• Sanctions Compliance: Not explicitly detailed beyond general compliance with U.S. economic and trade sanctions.

Legal Proceedings: Natera, Inc. is involved in various legal matters, including patent infringement lawsuits (e.g., against CareDx, Inc., ArcherDX, Inc., Ravgen, Inc., Genosity Inc., NeoGenomics Laboratories, Inc., and Labcorp Holdings Inc.), false advertising claims (e.g., with CareDx, Inc. and Guardant Health, Inc.), and purported class action lawsuits related to patient billing and marketing. As of December 31, 2025, the aggregate accrual for probable and estimable legal contingencies is approximately $32.6 million.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: The tax benefit for income taxes in 2025 was 22.35%.
• Geographic Tax Planning: Loss before income taxes is substantially all within the United States.
• Tax Reform Impact: The One Big Beautiful Bill Act (OB3), signed July 4, 2025, permanently eliminates the requirement to capitalize and amortize U.S.-based research and experimental expenditures over five years, making them fully deductible in the period incurred. Natera, Inc. expects to make a Sec. 59(e) election to capitalize and amortize current year domestic R&D expense over 10 years.
• Net Operating Loss (NOL) Carryforwards: As of December 31, 2025, Natera, Inc. had federal, state, and foreign NOL carryforwards of approximately $2.0 billion, $1.4 billion, and $4.5 million, respectively. Approximately $1.7 billion of federal NOLs can be carried forward indefinitely.
• Research and Development Tax Credit Carryforwards: Federal R&D credit carryforwards of approximately $83.6 million and state R&D credit carryforwards of approximately $48.9 million as of December 31, 2025.
• Valuation Allowance: A valuation allowance of $868.0 million was established against deferred tax assets as of December 31, 2025, due to uncertainty regarding their realization, partially released in connection with the Foresight Diagnostics, Inc. acquisition.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: Natera, Inc. maintains product and professional liability insurance, as well as indemnification agreements, to limit exposure to claims.
• Risk Transfer Mechanisms: Not explicitly detailed beyond insurance and indemnification.